News

Seattle Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Company’s New Drug Application (NDA) for the investigational…
Read More...

Soligenix, Inc. announced that its RiVax (heat stable ricin toxin vaccine) development program for prevention of ricin intoxication has received "Fast Track" designation from the US…
Read More...

Vir Biotechnology, Inc. a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, announced that it has identified two…
Read More...

Comar, a specialty packaging, device, and component supplier serving the Medical, Pharmaceutical, Consumer Healthcare, Personal and Home Care, Food and Beverage, and other niche market…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the pivotal Phase 3 KEYNOTE-355 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with…
Read More...

OSE Immunotherapeutics announced a new collaboration agreement with deep technology innovative start-up MAbSilico, located in Tours, France, to use artificial intelligence (AI)-based…
Read More...

Dr. Reddy’s Laboratories Ltd. announced that it has entered into a definitive agreement with Wockhardt Limited to acquire select divisions of its branded generics business in India and…
Read More...

ALX Oncology announced the closing of a $105 million Series C equity financing. Vivo Capital was the lead investor with other new investors including funds managed by Logos Capital,…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is a MET inhibitor…
Read More...

Cannabics Pharmaceuticals Inc. announced that it has signed a Memorandum Of Understanding with RCK Medical Cannabis to develop cannabis chemovars targeted to treat gastro intestinal…
Read More...

Astellas Pharma Inc. and Pfizer Inc. announced results of the final overall survival (OS) analysis from the Phase 3 PROSPER trial, which evaluated XTANDI (enzalutamide) plus androgen…
Read More...

Bayer AG announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an international service provider…
Read More...

Advaxis, Inc. and Personalis Inc. announced a collaboration to leverage Personalis’ ImmunoID NeXT Platform in Advaxis’ ongoing Phase 1/2 ADXS-503 (HOT Lung) program evaluating ADXS-503…
Read More...

Ligand Pharmaceuticals Incorporated announces the signing of an agreement whereby Ligand will acquire the core assets of Icagen, Inc.’s North Carolina operations, including partnered…
Read More...

LakePharma, Inc. and NJ Biopharmaceuticals LLC  announce the formation of a strategic alliance to offer streamlined antibody-drug conjugate (ADC) development solutions for the…
Read More...

ReForm Biologics LLC, a pharmaceutical technology company developing innovative platforms to improve biologic formulations and MilliporeSigma announced a global license agreement and…
Read More...

Catalent, Inc. announced that it had completed its acquisition of MaSTherCell Global Inc., positioning Catalent as a premier technology, development and manufacturing partner for…
Read More...

Biohaven Pharmaceutical Holding Company Ltd. reported negative topline results from its Phase 3 clinical trial evaluating troriluzole compared to placebo for the treatment of patients…
Read More...

Eli Lilly and Company announced that the analysis performed by Washington University School of Medicine in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study showed…
Read More...

Kite, a Gilead Company announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for…
Read More...